Network-Scored HIV Immunogen Composition Against Epitope Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high rate of viral mutation in HIV allows the virus to escape from vaccine-induced and host immune responses, particularly affecting cytotoxic T lymphocyte responses, necessitating the identification of specific HIV proteome epitopes that are resistant to mutation for effective recognition and killing of virally infected cells.
Innovation Solution
A multi-epitope T cell immunogen composition comprising highly networked HIV CTL epitopes, identified using a structure-based network analysis algorithm, which quantifies the topological importance of amino acid residues within the HIV proteome to design effective immunogens that persistently target and kill HIV-infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine approaches are used, then initial immune response is generated, but the virus escapes through mutation
Solution Approach 1:
The patent segments the HIV proteome into multiple distinct epitope regions and identifies highly networked epitopes that are structurally interconnected. By dividing the viral protein into targetable epitope segments with high network scores, the vaccine can induce T cell responses against multiple stable regions, making it harder for the virus to escape through single-point mutations.
Solution Approach 2:
The patent changes the selection parameter from conventional epitope prediction methods to a structure-based network score metric. By using network score thresholds (e.g., ≥3.06) to identify epitopes with high topological importance and structural stability, the method selects epitopes that are less prone to mutation, thereby improving the reliability of immune recognition over time.
2Reliability
If epitopes with high network scores are selected, then mutation resistance is improved, but identification complexity increases
Solution Approach 1:
The patent replaces conventional epitope prediction methods (based on sequence alignment and immunogenicity scores) with a structure-based network analysis system. This substitution uses protein three-dimensional structural data and network theory metrics to objectively identify stable epitopes, providing a more reliable though computationally intensive method for predicting mutation-resistant targets.
Solution Approach 2:
The patent introduces new evaluation parameters including network score, topological importance, and structural stability metrics. By changing from sequence-based to structure-based parameters, the method achieves better epitope selection accuracy, though it requires access to three-dimensional structural data and network analysis computational resources.
3Adaptability or versatility
If multiple highly networked epitopes are included, then immune coverage is improved, but immunogen complexity increases
Solution Approach 1:
The patent designs multi-epitope immunogens that can target multiple HLA alleles and HIV proteome regions simultaneously. By incorporating epitopes restricted by different HLA class I molecules (HLA-A, HLA-B, HLA-C) and selecting epitopes from various viral proteins (Gag, Pol, Nef, Vif, Vpr, Tat, Rev), the vaccine achieves broad immune coverage across diverse human populations and viral strains.
Solution Approach 2:
The patent creates composite immunogen structures that combine multiple highly networked epitopes from different HIV proteins and restricted by different HLA alleles. These composite immunogens function as multi-component vaccines that elicit coordinated T cell responses against multiple viral targets, enhancing overall immune coverage and adaptability to viral variation.
Data Source
AI summary
A method of preventing or treating HIV in a subject includes selecting two or more HIV CTL epitopes from an HIV proteome that have a network score that meets a threshold value. The network score for a given epitope can be determined by generating at least one network representing protein structure, calculating a set of network parameters, combining the network parameters to determine a network score for each amino acid residue in the protein structure, generating a network score for each of a plurality of epitopes as a weighted linear combination of the amino acid residues of the epitopes, and selecting two or more epitopes according to their network score. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected HIV CTL epitopes.